U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. CPG Sec. 390.225 Early Defects or Noncompliance - 21 CFR 1004.6
  1. Search for FDA Guidance Documents

COMPLIANCE POLICY GUIDE (CPG)

CPG Sec. 390.225 Early Defects or Noncompliance - 21 CFR 1004.6 February 2013

Final
Docket Number:
FDA-2020-D-0957
Issued by:
Guidance Issuing Office
Center for Devices and Radiological Health

BACKGROUND:

If a product defect or noncompliance with the Federal standard is discovered by a manufacturer (or x-ray equipment assembler), he may wish to initiate repair simultaneously with notification to FDA so that down time is minimized. Part 1003 requires that FDA (and others) be notified of radiation safety defects or failure to comply with a performance standard, and Part 1004 requires that the manufacturer must repair, replace, or refund the purchase price of a defective or noncompliant product. The correction of the product must be performed pursuant to a plan approved by FDA (21 CFR 1004.6

POLICY

The *Federal Food, Drug, and Cosmetic Act, Subchapter C-Electronic Product Radiation Control,* and the regulations, do not preclude purchaser notification and correction of a defect or noncompliance prior to the approval of a plan; however, such corrective action would still be subject to a plan approved by FDA. To avoid the possibility of having to prepare and implement a second corrective action plan, a manufacturer or assembler should communicate with the Food and Drug Administration as early as possible after discovery of a defect or failure to comply.

*Material between asterisks is new or revised*

Issued: 10/1/80
Revised: 3/95

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2020-D-0957.

Back to Top